跳转至内容
Merck
HomeWebinarsAmorphous Stability & Mesoporous Silica

Amorphous Stability & Mesoporous Silica



WEBINAR

Historically, polymeric solid dispersions have been the technology of choice for amorphous formulation. However, this approach may have some downfalls when considering the ability to stabilize compounds in the amorphous form, especially poor glass former compounds with a high propensity to re-crystallize. This webinar will examine amorphous stability from a theoretical perspective in the context of polymeric solid dispersions and mesoporous silica formulations. Finally, we will present recent data demonstrating the potential of mesoporous silica for superior amorphous stabilization of poor glass formers.

In this webinar, you will learn:

  • Why amorphous stability is a critical consideration in formulation development for poorly soluble compounds
  • How amorphous stability can be assessed using the glass-forming ability
  • Why poor glass former compounds can be challenging to formulate with traditional polymeric solid dispersions
  • How mesoporous silica can stabilize poor glass formers via nanoconfinement and reduction in molecular mobility

Speaker

Daniel Joseph Price, Ph.D.

Daniel Joseph Price, Ph.D.

Merck

Strategic Marketing Manager

Daniel Joseph Price is a strategic marketing manager for our portfolio of solubility enhancement excipients. Prior to his current role, Daniel was a Marie Curie Fellow, conducting research on solubility enhancement with amorphous formulations. Daniel is an active member of several academia/industrial consortia on the topics of innovation in oral solid dosage forms and has published extensively on the topic in peer-reviewed journals. Daniel has a B.S. and an M.S. in chemistry from the University of Leeds and a Ph.D. in pharmaceutical technology from Frankfurt Goethe University.

 

Webinar Information

Pharma and biopharma manufacturing

  • Solid Formulation Strategies
  • 期间:50min

  • 语言:English

  • 场次 1:往期 February 13, 2020

    Watch Now


登录以继续。

如要继续阅读,请登录或创建帐户。

暂无帐户?